EUVIMEDEUVIMED entdecken
Open Access

Lesion Absorbed Dose–Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy

Milan Grkovski, Simone S Krebs, Joseph A O'Donoghue, Jonathan Kuten, Audrey Mauguen, Parnian Shobeiri, Daniel Lafontaine, Maria Thor, Finn Augensen, Josef J Fox, Neeta Pandit-Taskar, Mark P Dunphy und 3 weitere

Journal of Nuclear Medicine · 2025-10 · 66 (10) · 1622-1630

DOI: 10.2967/jnumed.125.270170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 07.08.2025. Verfasst von Milan Grkovski und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; grkovskm@mskcc.org schoderh@mskcc.org. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Heterocyclic Compounds, 1-Ring, Dipeptides, Radiopharmaceuticals. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The relationship between lesion absorbed dose (AD) and response in patients with metastatic castration-resistant prostate cancer undergoing [177Lu]Lu-PSMA-617 radiopharmaceutical therapy (RPT) remains poorly understood. The objective of this work was to investigate the AD-response relationship at both the patient and lesion levels.

Methods

Sixty-five patients underwent serial SPECT/CT imaging after receiving 7.31 ± 0.27 GBq of [177Lu]Lu-PSMA-617. Single-time-point (STP) (Hänscheid approximation at 72 h) and multiple-time-point voxelwise dosimetry were performed. Patient response was evaluated by changes in serum prostate-specific antigen level before and after cycle 1 of RPT. The response of individual lesions was evaluated by the change in the SUVmax before, during, and after RPT with [68Ga]Ga-PSMA-11 PET/CT.

Results

Baseline PET and SPECT lesion SUVmax were strongly correlated (Pearson r, 0.74; n = 1364 lesions). Kidney ADs were relatively low (0.28 ± 0.12 Gy/GBq). No significant decrease in estimated glomerular filtration rate was observed 1 y after RPT. On average, STP dosimetry underestimated the AD by 8%. A moderate negative relationship was observed between the mean lesion AD for an individual patient (Spearman ρ, -0.33; n = 63) and lesion (Spearman ρ, -0.30; n = 681) responses. Patients receiving a higher mean AD (>7.5 Gy) had a significantly better prostate-specific antigen response (median, 70% vs. -5%; P < 0.001; unpaired t test) and longer biochemical progression-free survival (median, 4.1 mo vs. 1.6 mo; P = 0.005; unpaired t test) compared with patients whose mean AD was less than 7.5 Gy, respectively.

Conclusion

A moderate AD-response relationship was observed in patients with metastatic castration-resistant prostate cancer undergoing [177Lu]Lu-PSMA-617 RPT. The feasibility of STP dosimetry facilitates its implementation for treatment personalization. Kidney ADs may be reduced with abundant hydration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantHeterocyclic Compounds, 1-RingDipeptidesRadiopharmaceuticalsLutetiumHumansMaleAgedMiddle AgedNeoplasm MetastasisDose-Response Relationship, RadiationSingle Photon Emission Computed Tomography Computed TomographyAged, 80 and overProstate-Specific AntigenRadioisotopesRadiometryTreatment Outcome

Stichwörter der Autor:innen

[177Lu]Lu-PSMA-617[68Ga]Ga-PSMA-11dose–response relationshipmetastatic prostate cancer

Substanzen

Heterocyclic Compounds, 1-RingDipeptidesRadiopharmaceuticalsLutetiumLutetium-177PluvictoPSMA-617Prostate-Specific AntigenRadioisotopes

Autor:innen und Institutionen

  • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; grkovskm@mskcc.org schoderh@mskcc.org.
  • Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Nuclear Medicine, Division of Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York; and.
  • Nuclear Medicine Division, Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Förderung

  • NCI NIH HHS

Zitieren

APA

Grkovski, M., Krebs, S. S., O'Donoghue, J. A., Kuten, J., Mauguen, A., Shobeiri, P., Lafontaine, D., Thor, M., Augensen, F., Fox, J. J., Pandit-Taskar, N., Dunphy, M. P., Bodei, L., Humm, J. L., & Schöder, H. (2025). Lesion Absorbed Dose–Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 66(10), 1622-1630. https://doi.org/10.2967/jnumed.125.270170

Vancouver

Grkovski M, Krebs SS, O'Donoghue JA, Kuten J, Mauguen A, Shobeiri P, et al. Lesion Absorbed Dose–Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy. Journal of Nuclear Medicine. 2025;66(10):1622-1630. doi:10.2967/jnumed.125.270170

BibTeX
@article{Grkovski2025,
  author = {Grkovski, Milan and Krebs, Simone S and O'Donoghue, Joseph A and Kuten, Jonathan and Mauguen, Audrey and Shobeiri, Parnian and Lafontaine, Daniel and Thor, Maria and Augensen, Finn and Fox, Josef J and Pandit-Taskar, Neeta and Dunphy, Mark P and Bodei, Lisa and Humm, John L and Schöder, Heiko},
  title = {Lesion Absorbed Dose–Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {10},
  pages = {1622--1630},
  doi = {10.2967/jnumed.125.270170}
}
Kostenlos starten →